AX-2025-019684
Melanotan II · 10 mg declared · Tianjin Finder Chemical Co., Ltd. · lot TFC-2410-R2237
- Report ID
- AX-2025-019684
- Compound
- Melanotan II
- Compound class
- Melanocortin-receptor peptides
- Supplier
- TFC — Tianjin Finder Chemical Co., Ltd.
- Batch / lot
- TFC-2410-R2237
- Declared label claim
- 10mg
- Laboratory
- Medutest
- Assay date
- 22 Mar 2025
- Submitted
- 08 Apr 2025
- Quarter
- 2025-Q1
- Submitter
- ha.diallo
- Sample provenance
- Buyer-sourced
Results
Measured against the index acceptance specification for the melanocortin-receptor peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.
| Parameter | Method | Result | Unit | Index spec | |
|---|---|---|---|---|---|
| Purity | RP-HPLC, 25 min gradient, 214 nm | 99.33 | % area | ≥ 98.5 | PASS |
| Total impurities | RP-HPLC, sum of reported peaks | 0.67 | % area | ≤ 1.5 | PASS |
| Largest single impurity | RP-HPLC — des-acetyl MT-II (−42 Da) | 0.25 | % area | ≤ 1.00 | PASS |
| Identity | not ordered on this submission | not determined | — | required for VERIFIED status | NOT TESTED |
| Total peptide content | by difference from the gravimetric mass balance | 88.15 | %w/w | — | NOT TESTED |
| Target-compound content | total peptide content × purity | 87.56 | %w/w | — | NOT TESTED |
| Gross fill (as weighed) | five-place balance, under nitrogen | 10.96 | mg | 10 mg declared | NOT TESTED |
| Recovered target peptide | gross fill × target content | 9.597 | mg | 10 mg claim | NOT TESTED |
| Recovery against label claim | recovered ÷ claim | 96.0 | % | 90.0 – 110.0 | PASS |
| Water content | Karl Fischer, coulometric, duplicate | 5.55 | % | ≤ 8.0 | PASS |
| Counter-ion (acetate) | anion-exchange ion chromatography | 5.39 | % | ≤ 10.0 | PASS |
| Residual solvent + inorganic residue | estimated — see /methods/residual-solvents-q3c/ | 0.91 | % | — | NOT TESTED |
| Endotoxin | kinetic chromogenic LAL | 1.30 | EU/mg | ≤ 5.0 | PASS |
| Sterility | membrane filtration, USP <71>, 14 d | No growth at 14 d | — | no growth | PASS |
| Appearance | visual, diffuse light, black and white background | Off-white lyophilised cake, intact | — | white to off-white intact cake | PASS |
| Reconstitution clarity | reconstituted per submitter procedure | Clear, colourless, no visible particulates | — | clear, no visible particulates | PASS |
| pH (reconstituted, 1 mg/mL) | potentiometric, two-point calibration | 6.34 | — | 2.5 – 8.0 | PASS |
| Retention time (observed) | RP-HPLC, 25 min gradient | 8.46 | min | 8.33 ± 0.25 (normalised) | PASS |
| Peak asymmetry (10 % height) | Ph. Eur. 2.2.46 | 1.16 | — | 0.80 – 1.50 | PASS |
| Plate count, main peak | N = 5.54 (t/w½)² | 63,391 | — | ≥ 20,000 | PASS |
| Resolution to nearest impurity | vs [L-Phe7]-diastereomer | 0.97 | — | no index criterion | REPORTED |
Chromatogram and peak integration
The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.
| # | Peak | RT | Area (µV·s) | % area | Δ mass (Da) |
|---|---|---|---|---|---|
| 1 | Melanotan II — main peak | 8.46 | 4,827,746 | 99.33 | — |
| 2 | des-acetyl MT-II (−42 Da) | 8.06 | 12,151 | 0.25 | -42.011 |
| 3 | linear (open-lactam) precursor (+18 Da) | 7.84 | 11,179 | 0.23 | +18.011 |
| 4 | oxidised Trp (+16 Da) | 8.16 | 5,346 | 0.11 | +15.995 |
| 5 | MT-II dimer (head-to-tail) | 10.42 | 2,430 | 0.05 | +1023.540 |
| 6 | [L-Phe7]-diastereomer | 8.33 | 1,458 | 0.03 | 0.000 |
| Closure check — purity + Σ impurities | 100.00 | CLOSES | |||
Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.
Gravimetric mass balance
Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.
| Component | Determination | %w/w of cake |
|---|---|---|
| Water | Karl Fischer | 5.55 |
| Counter-ion (acetate) | ion chromatography | 5.39 |
| Residual solvent + inorganic residue | estimated | 0.91 |
| Total peptide content | by difference | 88.15 |
| Total | 100.00 CLOSES | |
Supplier certificate, as declared
The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.
| Figure | Supplier COA | This report | Index note |
|---|---|---|---|
| Purity (% area) | 99.66 | 99.33 | divergence +0.41 pp vs batch median |
| Total impurities (% area) | 0.34 | 0.67 | |
| Largest single impurity (% area) | 0.19 | 0.25 | |
| Water (%) | not stated | 5.55 | |
| Counter-ion (%) | 2.6 | 5.39 | |
| Peptide content (%w/w) | 93.3 | 88.15 | |
| Endotoxin (EU/mg) | 0.54 | 1.30 | |
| Method stated on certificate | NO | — | no method section — the result cannot be reconciled against any other |
Provenance and caveats
Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.
- Sample provenance
- Buyer-sourced
- Evidentiary weight
- Strongest available evidence in this index.
- Chain of custody
- Retail purchase → submitter (ambient, 28 d) → laboratory (hand-carried, 2 d) → assay.
- Assay date
- 22 Mar 2025
- Submitted to the index
- 08 Apr 2025
- Laboratory
- Medutest, Ljubljana, Slovenia
- Method basis
- 25 min gradient · unit-resolution MS
- Verification status
- PURITY ONLY
Annotations 3
Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.
Related records
Same batch — lot TFC-2410-R2237 n=3
| Report | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|
| AX-2025-019685 | TFC-2410-R2237 | PeptideMeter | 2025-Q1 | 99.25 | 6.00 | 93.5 | Buyer-sourced | 0 | PASS |
| AX-2025-019686 | TFC-2410-R2237 | Janoshik | 2025-Q1 | 99.11 | 5.31 | 100.9 | Buyer-sourced | 0 | PASS |
Cross-sections
| Report | Supplier | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-042757 | GGPeps | GGPE-2603-P1474 | Janoshik | 2026-Q3 | 99.54 | 6.78 | 92.0 | Buyer-sourced | 0 | PASS |
| AX-2026-042756 | GGPeps | GGPE-2603-P1474 | Nordanalyt | 2026-Q3 | 99.17 | 7.04 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042755 | GGPeps | GGPE-2603-P1474 | Nordanalyt | 2026-Q3 | 99.25 | 6.58 | 90.4 | Buyer-sourced | 0 | PASS |
| AX-2026-042760 | GGPeps | GGPE-2603-P1474 | Medutest | 2026-Q3 | 99.43 | 7.02 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042758 | GGPeps | GGPE-2603-P1474 | PeptideMeter | 2026-Q3 | 99.23 | 6.96 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042759 | GGPeps | GGPE-2603-P1474 | Janoshik | 2026-Q3 | 99.15 | 6.71 | 105.1 | Buyer-sourced | 0 | PASS |
| AX-2026-042168 | JEEP | JEEP-2604-R9103 | Nordanalyt | 2026-Q2 | 99.40 | 5.71 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042164 | JEEP | JEEP-2604-R9103 | Janoshik | 2026-Q2 | 99.54 | 5.23 | — | Buyer-sourced | 1 | MARGINAL |
| Report | Compound | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-042265 | Humanin (HNG) | TFC-2605-U1300 | PeptideMeter | 2026-Q3 | 99.52 | 6.31 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042222 | SS-31 (Elamipretide) | TFC-2607-R9099 | VendorInvestigate | 2026-Q3 | 99.46 | 5.41 | 102.6 | Buyer-sourced | 0 | PASS |
| AX-2026-042236 | Humanin (HNG) | TFC-2608-S9940 | Nordanalyt | 2026-Q3 | 98.64 | 1.80 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042282 | Retatrutide | TFC-2608-J1156 | Janoshik | 2026-Q3 | 98.54 | 4.27 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042226 | SS-31 (Elamipretide) | TFC-2607-R9099 | Janoshik | 2026-Q3 | 99.62 | 5.47 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042217 | Semaglutide | TFC-2604-X9037 | PeptideMeter | 2026-Q3 | 98.95 | 4.61 | 96.9 | Buyer-sourced | 0 | PASS |
| AX-2026-042339 | Sermorelin | TFC-2605-Y2176 | Kestrel | 2026-Q3 | 99.93 | 4.14 | — | Supplier-supplied | 1 | FAIL |
| AX-2026-042214 | Semaglutide | TFC-2604-X9037 | Kestrel | 2026-Q3 | 99.87 | 4.66 | 103.1 | Laboratory-retained | 0 | PASS |